SCHEMBL4496201

SCHEMBL4496201

CC(N)C(=O)Nc1ccc2[nH]c(-c3ccccc3-c3nc4cc(NC(=O)C(C)N)ccc4[nH]3)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
TAAR1 Q96RJ0 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ADORA2A P29274 1/20 0.45
XIAP P98170 1/20 0.45
KDM4E B2RXH2 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 1/20 0.44
NR2E3 Q9Y5X4 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
POLB P06746 1/20 0.43
HPSE Q9Y251 1/20 0.42
NPC1 O15118 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496122 0.83 KDM4E (0.61) TP53MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL2242067 0.79 NR2E3 (0.60) TP53MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL4496830 0.78 PTPRC (0.53) TP53RXFP1MEN1KMT2AKDM4E
SCHEMBL4483537 0.78 KDM4E (0.54) TP53RXFP1MEN1KMT2AKDM4E
SCHEMBL4480173 0.77 DGAT1 (0.60) TP53RXFP1MEN1KMT2AKDM4E
SCHEMBL4507119 0.74 COMT (0.67) MEN1KMT2AADORA2AKDM4EALDH1A1
SCHEMBL23613495 0.74 KRAS (0.48) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL2245235 0.73 SMN1; SMN2 (0.58) TP53MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL4496027 0.73 KDM4E (0.65) TP53RXFP1MEN1KMT2AKDM4E
SCHEMBL5953387 0.73 PDPK1 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 US disclosed
US-7132439-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2006-11-07 US disclosed
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 TP53 3963/4885RXFP1 4383/4885TAAR1 2856/4885
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 TP53 3963/4885RXFP1 4383/4885TAAR1 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.